Short answer
MANNKIND CORP (MNKD) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). August 5, 2026 press release covers MannKind’s fiscal-year 2026 results.
MANNKIND CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- August 5, 2026 press release covers MannKind’s fiscal-year 2026 results
- Key financial figures and management commentary are contained in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $109.4M, up 43%, led by $22.2M Furoscix sales and $35.0M collaborations and services
- Afrezza sales fell 7% to $17.0M, while pediatric approval and early prescribing by 1 in 3 top-100 pediatric insulin writers support recovery potential
- Furoscix ReadyFlow FDA approval expands heart-failure and CKD opportunity, with commercial availability expected in late August
- GAAP net loss $19.0M versus $0.7M income, driven by $11.9M interest expense and $58.3M SG&A
- $50M private placement funds the $45M Furoscix ReadyFlow CVR payment, while June 30 cash, equivalents and investments totaled $111M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MANNKIND CORP 8-K filings
Get the next MNKD 8-K as it lands
Follow MNKD for push alerts, or ask the research agent what this filing means.